Ming Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ming Lu has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Lun-Xiu Qin
Department of General Surgery, Hepatobiliary Surgery Center, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai, China
7 shared publications Lu Lu
Hepatobiliary Surgery Center, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, 12 Urumqi Road, Shanghai 200040, China
6 shared publicationsWen-Wei Zhu
General Surgery Department of Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China
5 shared publicationsHu-Liang Jia
General Surgery Department of Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China
4 shared publications- Qiongzhu Dong
Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer, Shanghai Municipal Health Commission (SMHC), Department of Hepatobiliary and Pancreatic Surgery, Minhang Hospital, Fudan University, China
4 shared publications - Jinhong Chen
Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital and Cancer Metastasis Institute, Fudan University, Shanghai, China
3 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Nature Communications
ACAT1/SOAT1 governs mitochondrial dynamics and thermogenesis via the mTOR-MFN2-USP2 axis in brown adipocytes
- 8 October 2026
- Published by Springer Nature in Nature Communications
Open AccessACAT1/SOAT1 governs mitochondrial dynamics and thermogenesis via the mTOR-MFN2-USP2 axis in brown adipocytes
- 10 August 2026
- Published by Wolters Kluwer Health in Hepatology
Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis
Background and Aims: Liver fibrosis is a global health issue with unclear unified drivers. The RNA-binding protein hnRNPK is critical for hepatic homeostasis, but its role in chronic fibrosis remains undefined. This study investigated hnRNPK-mediated splicing dysregulation in liver fibrosis and its therapeutic potential. Approach and Results: We mapped hepatocellular hnRNPK expression across a broad spectrum of human and murine fibrotic etiologies. Mechanistic insights were obtained by integrating snRNA-seq, hepatocyte-specific alternative splicing profiling, untargeted and spatial metabolomics, and 3D mitochondrial reconstruction using AT-SEM. We identified reduced hepatocellular hnRNPK abundance as a conserved hallmark of liver fibrosis across distinct pathogenic insults, including MASH, ALD, HBV, and DILI. Hepatocyte-specific Hnrnpk ablation in mice induced aberrant Opa1 splicing, specifically promoting exon 4b inclusion. This disrupted the balance of OPA1 isoforms, depleting L-OPA1 and driving severe mitochondrial fragmentation characterized by distinct “spheroid” ultrastructures. This loss of mitochondrial integrity triggered HSC activation through the cytosolic mtDNA–cGAS–STING pro-inflammatory signaling cascade and the mitochondria-containing pellet. Notably, restoring the hnRNPK– Opa1 axis via AAV-mediated overexpression of Hnrnpk or the Opa1 -Δ4b isoform (lacking exon 4b), together with pharmacological promotion of mitochondrial fusion, effectively arrested and regressed established liver fibrosis in multiple murine models. Conclusions: Our findings establish the loss of hnRNPK as a central, unifying mechanism in liver fibrogenesis. By governing the Opa1 splicing axis, hnRNPK maintains mitochondrial integrity and prevents the pro-inflammatory signaling and secretome that fuel HSC activation. Targeting this RNA–mitochondria axis represents a potent, etiology-independent therapeutic strategy for chronic liver disease.
- 10 August 2026
- Published by Wolters Kluwer Health in Hepatology
Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis
Background and Aims: Liver fibrosis is a global health issue with unclear unified drivers. The RNA-binding protein hnRNPK is critical for hepatic homeostasis, but its role in chronic fibrosis remains undefined. This study investigated hnRNPK-mediated splicing dysregulation in liver fibrosis and its therapeutic potential. Approach and Results: We mapped hepatocellular hnRNPK expression across a broad spectrum of human and murine fibrotic etiologies. Mechanistic insights were obtained by integrating snRNA-seq, hepatocyte-specific alternative splicing profiling, untargeted and spatial metabolomics, and 3D mitochondrial reconstruction using AT-SEM. We identified reduced hepatocellular hnRNPK abundance as a conserved hallmark of liver fibrosis across distinct pathogenic insults, including MASH, ALD, HBV, and DILI. Hepatocyte-specific Hnrnpk ablation in mice induced aberrant Opa1 splicing, specifically promoting exon 4b inclusion. This disrupted the balance of OPA1 isoforms, depleting L-OPA1 and driving severe mitochondrial fragmentation characterized by distinct “spheroid” ultrastructures. This loss of mitochondrial integrity triggered HSC activation through the cytosolic mtDNA–cGAS–STING pro-inflammatory signaling cascade and the mitochondria-containing pellet. Notably, restoring the hnRNPK– Opa1 axis via AAV-mediated overexpression of Hnrnpk or the Opa1 -Δ4b isoform (lacking exon 4b), together with pharmacological promotion of mitochondrial fusion, effectively arrested and regressed established liver fibrosis in multiple murine models. Conclusions: Our findings establish the loss of hnRNPK as a central, unifying mechanism in liver fibrogenesis. By governing the Opa1 splicing axis, hnRNPK maintains mitochondrial integrity and prevents the pro-inflammatory signaling and secretome that fuel HSC activation. Targeting this RNA–mitochondria axis represents a potent, etiology-independent therapeutic strategy for chronic liver disease.
- Open Access
- 15 April 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (8)
Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance
Complete response is rarely observed in lung cancer molecular targeted therapy, despite great clinical success. Here, we found that molecular therapy targeted toward EGFR mutant, KRAS mutant, or ALK fusion lung cancer induced cholesterol biosynthesis, which promoted cancer cells to enter dormancy and thus escape drug killing. Combined statin treatments effectively blocked cholesterol biosynthesis, prevented cancer cells from entering dormancy, and thus resulted in dramatic tumor regression. We further identified a subpopulation of cycling cancer cells that persisted during molecular targeted therapy and remained sensitive to aurora kinase inhibitors. Triple-targeting cholesterol biosynthesis, aurora kinase, and individual oncogenic drivers almost eradicated all the cancer cells. Therapy-induced cancer dormancy was mainly attributed to activation of unfolded protein response, specifically the PERK-eIF2α axis, which triggers cholesterol biosynthesis and AKT signaling. Collectively, this work uncovers an unexpected role of a therapy-induced prosurvival program in promoting cancer dormancy and provides a potentially effective strategy to prevent drug resistance.
- 15 April 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (8)
Open AccessTherapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance
Complete response is rarely observed in lung cancer molecular targeted therapy, despite great clinical success. Here, we found that molecular therapy targeted toward EGFR mutant, KRAS mutant, or ALK fusion lung cancer induced cholesterol biosynthesis, which promoted cancer cells to enter dormancy and thus escape drug killing. Combined statin treatments effectively blocked cholesterol biosynthesis, prevented cancer cells from entering dormancy, and thus resulted in dramatic tumor regression. We further identified a subpopulation of cycling cancer cells that persisted during molecular targeted therapy and remained sensitive to aurora kinase inhibitors. Triple-targeting cholesterol biosynthesis, aurora kinase, and individual oncogenic drivers almost eradicated all the cancer cells. Therapy-induced cancer dormancy was mainly attributed to activation of unfolded protein response, specifically the PERK-eIF2α axis, which triggers cholesterol biosynthesis and AKT signaling. Collectively, this work uncovers an unexpected role of a therapy-induced prosurvival program in promoting cancer dormancy and provides a potentially effective strategy to prevent drug resistance.
- 20 October 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (11) , 2268-2283
Tumour-associated macrophages serve as an acetate reservoir to drive hepatocellular carcinoma metastasis
Increased acetyl-coenzyme A (acetyl-CoA) generation facilitates cancer metastasis and represents a critical metabolic characteristic of metastatic cancers. To maintain high acetyl-CoA levels, cancer cells often enhance the uptake of acetate for acetyl-CoA biosynthesis. However, the microenvironmental source of acetate remains largely unknown. Here we demonstrate that acetate is secreted by tumour-associated macrophages (TAMs) and taken up by hepatocellular carcinoma (HCC) cells to support acetate accumulation. Mechanistically, HCC cell-derived lactate activates the lipid peroxidation–aldehyde dehydrogenase 2 (ALDH2) pathway in TAMs, which promotes the TAMs’ acetate production and secretion. Inhibition of ALDH2 or of lipid peroxidation in TAMs abrogates acetate-induced migration of HCC cells in vitro. In an orthotopic HCC model involving male mice, genetic ablation of ALDH2 in TAMs reduces HCC cell acetate levels and HCC lung metastases. Collectively, our findings reveal a metabolic interaction between HCC cells and TAMs—involving lactate, lipid peroxidation and acetate—and position TAMs as an acetate reservoir that drives HCC metastasis.
- 20 October 2025
- Published by Springer Nature in Nature Metabolism
- Vol. 7 (11) , 2268-2283
Tumour-associated macrophages serve as an acetate reservoir to drive hepatocellular carcinoma metastasis
Increased acetyl-coenzyme A (acetyl-CoA) generation facilitates cancer metastasis and represents a critical metabolic characteristic of metastatic cancers. To maintain high acetyl-CoA levels, cancer cells often enhance the uptake of acetate for acetyl-CoA biosynthesis. However, the microenvironmental source of acetate remains largely unknown. Here we demonstrate that acetate is secreted by tumour-associated macrophages (TAMs) and taken up by hepatocellular carcinoma (HCC) cells to support acetate accumulation. Mechanistically, HCC cell-derived lactate activates the lipid peroxidation–aldehyde dehydrogenase 2 (ALDH2) pathway in TAMs, which promotes the TAMs’ acetate production and secretion. Inhibition of ALDH2 or of lipid peroxidation in TAMs abrogates acetate-induced migration of HCC cells in vitro. In an orthotopic HCC model involving male mice, genetic ablation of ALDH2 in TAMs reduces HCC cell acetate levels and HCC lung metastases. Collectively, our findings reveal a metabolic interaction between HCC cells and TAMs—involving lactate, lipid peroxidation and acetate—and position TAMs as an acetate reservoir that drives HCC metastasis.
- 24 April 2024
- Published by Elsevier in Cancer Letters
- Vol. 592, 216903
Acetyl-CoA metabolic accumulation promotes hepatocellular carcinoma metastasis via enhancing CXCL1-dependent infiltration of tumor-associated neutrophils
- 24 April 2024
- Published by Elsevier in Cancer Letters
- Vol. 592, 216903
Acetyl-CoA metabolic accumulation promotes hepatocellular carcinoma metastasis via enhancing CXCL1-dependent infiltration of tumor-associated neutrophils
- Open Access
- 1 December 2023
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 14 (6) , 2448-2465
CYP1B1 promotes colorectal cancer liver metastasis by enhancing the growth of metastatic cancer cells via a fatty acids-dependent manner
Background: Liver metastasis (LM) accounts for most colorectal cancer (CRC)-related deaths. However, how metastatic CRC cells gain the ability to survive and grow in liver remains largely unknown. Methods: First, we screened differentially expressed genes (DEGs) between LM and paired primary tumors (PTs) in Gene Expression Omnibus (GEO) database, and identified cytochrome P450 1B1 (CYP1B1) as the only common differential gene. Then, we verified messenger RNA (mRNA) and protein expression level in clinical specimens. After constructing stable up-regulated CYP1B1 versions of HCT116 and RKO CRC cells and stable down-regulated CYP1B1 versions of SW480 and HT29 CRC cells, cell proliferation assays, subcutaneous tumor formation, and mouse LM models were used to comprehend its function. Next, we used RNA-seq to uncover specific mechanisms of growth; cell cycle, polymerase chain reaction (PCR), western blot (WB) and GEO series (GSE) datasets were used to verify its mechanism. Last, gas chromatography tandem mass spectrometry (GC-MS/MS) was adopted to examine which fatty acids were changed. Results: A significantly higher level of CYP1B1 was found in LM than in PT in paired clinical CRC LM samples (Pin vitro and in vivo were enhanced; LM of NOD.Cg-PrkdcscidIl2rgem1Smoc (NSG) mice were enhanced. And knockdown of CYP1B1 in SW480 and HT29 cells, cell proliferation abilities in vitro and in vivo were reduced; LM of NSG mice were declined (PMCM5, PCNA, and FEN1 genes, and G1/S transition in CRC cells. GC-MS/MS revealed long chain fatty acids (LCFAs) made a difference in SW480 knockdown group (P in vitro and in vivo were enhanced, and expressions of MCM5, PCNA, FEN1 were upregulated (PConclusions: CYP1B1 exerts a significant influence on LM of CRC by modulating tumor cell proliferation via “CYP1B1-LCFAs-G1/S transition”. This finding suggests CYP1B1 could be a promising target for CRC LM.
- 1 December 2023
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 14 (6) , 2448-2465
Open AccessCYP1B1 promotes colorectal cancer liver metastasis by enhancing the growth of metastatic cancer cells via a fatty acids-dependent manner
Background: Liver metastasis (LM) accounts for most colorectal cancer (CRC)-related deaths. However, how metastatic CRC cells gain the ability to survive and grow in liver remains largely unknown. Methods: First, we screened differentially expressed genes (DEGs) between LM and paired primary tumors (PTs) in Gene Expression Omnibus (GEO) database, and identified cytochrome P450 1B1 (CYP1B1) as the only common differential gene. Then, we verified messenger RNA (mRNA) and protein expression level in clinical specimens. After constructing stable up-regulated CYP1B1 versions of HCT116 and RKO CRC cells and stable down-regulated CYP1B1 versions of SW480 and HT29 CRC cells, cell proliferation assays, subcutaneous tumor formation, and mouse LM models were used to comprehend its function. Next, we used RNA-seq to uncover specific mechanisms of growth; cell cycle, polymerase chain reaction (PCR), western blot (WB) and GEO series (GSE) datasets were used to verify its mechanism. Last, gas chromatography tandem mass spectrometry (GC-MS/MS) was adopted to examine which fatty acids were changed. Results: A significantly higher level of CYP1B1 was found in LM than in PT in paired clinical CRC LM samples (Pin vitro and in vivo were enhanced; LM of NOD.Cg-PrkdcscidIl2rgem1Smoc (NSG) mice were enhanced. And knockdown of CYP1B1 in SW480 and HT29 cells, cell proliferation abilities in vitro and in vivo were reduced; LM of NSG mice were declined (PMCM5, PCNA, and FEN1 genes, and G1/S transition in CRC cells. GC-MS/MS revealed long chain fatty acids (LCFAs) made a difference in SW480 knockdown group (P in vitro and in vivo were enhanced, and expressions of MCM5, PCNA, FEN1 were upregulated (PConclusions: CYP1B1 exerts a significant influence on LM of CRC by modulating tumor cell proliferation via “CYP1B1-LCFAs-G1/S transition”. This finding suggests CYP1B1 could be a promising target for CRC LM.
- Open Access
- 19 April 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (3) , 110712
Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma
- 19 April 2022
- Published by Elsevier in Cell Reports
- Vol. 39 (3) , 110712
Open AccessCholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma
- 17 November 2020
- Published by Wiley in International Journal of Cancer
- Vol. 148 (5) , 1233-1244
S100 calcium‐binding protein A9 from tumor‐associated macrophage enhances cancer stem cell‐like properties of hepatocellular carcinoma
Tumor‐associated macrophages (TAMs) are crucial components of the tumor microenvironment. They play vital roles in hepatocellular carcinoma (HCC) progression. However, the interactions between TAMs and HCC cells have not been fully characterized. In this study, TAMs were induced using human monocytic cell line THP‐1 cells in vitro to investigate their functions in HCC progression. S100 calcium‐binding protein A9 (S100A9), an inflammatory microenvironment‐related secreted protein, was identified to be significantly upregulated in TAMs. S100A9 expression in tumor tissues was associated with poor survival of HCC patients. It could enhance the stem cell‐like properties of HepG2 and MHCC‐97H cells by activating nuclear factor‐kappa B signaling pathway through advanced glycosylation end product‐specific receptor in a Ca2+‐dependent manner. Furthermore, we found that, after treatment with S100A9, HepG2 and MHCC‐97H cells recruited more macrophages via chemokine (CC motif) ligand 2, which suggests a positive feedback between TAMs and HCC cells. Taken together, our findings reveal that TAMs could upregulate secreted protein S100A9 and enhance the stem cell‐like properties of HCC cells and provide a potential therapeutic target for combating HCC.
- 17 November 2020
- Published by Wiley in International Journal of Cancer
- Vol. 148 (5) , 1233-1244
S100 calcium‐binding protein A9 from tumor‐associated macrophage enhances cancer stem cell‐like properties of hepatocellular carcinoma
Tumor‐associated macrophages (TAMs) are crucial components of the tumor microenvironment. They play vital roles in hepatocellular carcinoma (HCC) progression. However, the interactions between TAMs and HCC cells have not been fully characterized. In this study, TAMs were induced using human monocytic cell line THP‐1 cells in vitro to investigate their functions in HCC progression. S100 calcium‐binding protein A9 (S100A9), an inflammatory microenvironment‐related secreted protein, was identified to be significantly upregulated in TAMs. S100A9 expression in tumor tissues was associated with poor survival of HCC patients. It could enhance the stem cell‐like properties of HepG2 and MHCC‐97H cells by activating nuclear factor‐kappa B signaling pathway through advanced glycosylation end product‐specific receptor in a Ca2+‐dependent manner. Furthermore, we found that, after treatment with S100A9, HepG2 and MHCC‐97H cells recruited more macrophages via chemokine (CC motif) ligand 2, which suggests a positive feedback between TAMs and HCC cells. Taken together, our findings reveal that TAMs could upregulate secreted protein S100A9 and enhance the stem cell‐like properties of HCC cells and provide a potential therapeutic target for combating HCC.
- Top Cited Papers
- 21 September 2020
- Published by Springer Nature in Nature Immunology
- Vol. 21 (11) , 1444-1455
Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis
Acquisition of a lipid-laden phenotype by immune cells has been defined in infectious diseases and atherosclerosis but remains largely uncharacterized in cancer. Here, in breast cancer models, we found that neutrophils are induced to accumulate neutral lipids upon interaction with resident mesenchymal cells in the premetastatic lung. Lung mesenchymal cells elicit this process through repressing the adipose triglyceride lipase (ATGL) activity in neutrophils in prostaglandin E2-dependent and -independent manners. In vivo, neutrophil-specific deletion of genes encoding ATGL or ATGL inhibitory factors altered neutrophil lipid profiles and breast tumor lung metastasis in mice. Mechanistically, lipids stored in lung neutrophils are transported to metastatic tumor cells through a macropinocytosis–lysosome pathway, endowing tumor cells with augmented survival and proliferative capacities. Pharmacological inhibition of macropinocytosis significantly reduced metastatic colonization by breast tumor cells in vivo. Collectively, our work reveals that neutrophils serve as an energy reservoir to fuel breast cancer lung metastasis.
- 21 September 2020
- Published by Springer Nature in Nature Immunology
- Vol. 21 (11) , 1444-1455
Top Cited PapersLung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis
Acquisition of a lipid-laden phenotype by immune cells has been defined in infectious diseases and atherosclerosis but remains largely uncharacterized in cancer. Here, in breast cancer models, we found that neutrophils are induced to accumulate neutral lipids upon interaction with resident mesenchymal cells in the premetastatic lung. Lung mesenchymal cells elicit this process through repressing the adipose triglyceride lipase (ATGL) activity in neutrophils in prostaglandin E2-dependent and -independent manners. In vivo, neutrophil-specific deletion of genes encoding ATGL or ATGL inhibitory factors altered neutrophil lipid profiles and breast tumor lung metastasis in mice. Mechanistically, lipids stored in lung neutrophils are transported to metastatic tumor cells through a macropinocytosis–lysosome pathway, endowing tumor cells with augmented survival and proliferative capacities. Pharmacological inhibition of macropinocytosis significantly reduced metastatic colonization by breast tumor cells in vivo. Collectively, our work reveals that neutrophils serve as an energy reservoir to fuel breast cancer lung metastasis.
- Open Access
- 1 September 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-14
Dual roles of neutrophils in metastatic colonization are governed by the host NK cell status
The role of neutrophils in solid tumor metastasis remains largely controversial. In preclinical models of solid tumors, both pro-metastatic and anti-metastatic effects of neutrophils have been reported. In this study, using mouse models of breast cancer, we demonstrate that the metastasis-modulating effects of neutrophils are dictated by the status of host natural killer (NK) cells. In NK cell-deficient mice, granulocyte colony-stimulating factor-expanded neutrophils show an inhibitory effect on the metastatic colonization of breast tumor cells in the lung. In contrast, in NK cell-competent mice, neutrophils facilitate metastatic colonization in the same tumor models. In an ex vivo neutrophil-NK cell-tumor cell tri-cell co-culture system, neutrophils are shown to potentially suppress the tumoricidal activity of NK cells, while neutrophils themselves are tumoricidal. Intriguingly, these two modulatory effects by neutrophils are both mediated by reactive oxygen species. Collectively, the absence or presence of NK cells, governs the net tumor-modulatory effects of neutrophils.
- 1 September 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-14
Open AccessDual roles of neutrophils in metastatic colonization are governed by the host NK cell status
The role of neutrophils in solid tumor metastasis remains largely controversial. In preclinical models of solid tumors, both pro-metastatic and anti-metastatic effects of neutrophils have been reported. In this study, using mouse models of breast cancer, we demonstrate that the metastasis-modulating effects of neutrophils are dictated by the status of host natural killer (NK) cells. In NK cell-deficient mice, granulocyte colony-stimulating factor-expanded neutrophils show an inhibitory effect on the metastatic colonization of breast tumor cells in the lung. In contrast, in NK cell-competent mice, neutrophils facilitate metastatic colonization in the same tumor models. In an ex vivo neutrophil-NK cell-tumor cell tri-cell co-culture system, neutrophils are shown to potentially suppress the tumoricidal activity of NK cells, while neutrophils themselves are tumoricidal. Intriguingly, these two modulatory effects by neutrophils are both mediated by reactive oxygen species. Collectively, the absence or presence of NK cells, governs the net tumor-modulatory effects of neutrophils.